Core Viewpoint - GLP-1 receptor agonists (GLP-1RAs) show potential benefits for overweight or obese rheumatoid arthritis (RA) patients, beyond their established use for obesity and type 2 diabetes treatment [4][6]. Group 1: Research Findings - A study published in ACR Open Rheumatology indicates that GLP-1RAs can reduce disease activity and improve cardiovascular risk indicators in RA patients with a BMI ≥ 27 [4][6]. - The study included 173 RA patients treated with GLP-1RAs and a control group of 42 patients who were prescribed but did not use the medication [6]. - Significant improvements were observed in various clinical endpoints for the treatment group compared to the control group, including: - Disease activity score decreased by an average of -0.03 vs +0.2 (P=0.03) - Visual analog scale pain score improved by -0.6 cm vs +1.3 cm (P<0.001) - Weight loss of -4.4 kg vs -1.2 kg (P<0.001) - Total cholesterol reduction of -10.3 mg/dL vs +0.3 mg/dL (P=0.04) - Hemoglobin A1c decrease of -0.3% vs -0.01% (P=0.03) [6][7]. Group 2: Implications and Recommendations - The study suggests that GLP-1RAs may provide independent cardiovascular benefits beyond weight loss, potentially alleviating obesity-related inflammation in RA patients [7]. - However, nearly one-third of the treatment group discontinued the medication, primarily due to gastrointestinal side effects and accessibility issues, which could hinder clinical benefits [7]. - The study highlights disparities in accessibility, noting a higher proportion of white patients in the treatment group (71% vs 47% in the control group), indicating structural barriers that may limit access for Black, Latino, and Asian patients [7]. - Future research should prioritize increasing sample diversity to better reflect the RA population and confirm the findings through more rigorous prospective studies [7][8].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 类风湿关节炎 （RA） 是一种自身免疫疾病，其特征为持续性滑膜炎和进行性软骨破坏。RA 的传统治疗方法主要包括抗炎药物。尽管这些疗法能够缓解症状，但 对许多患者而言往往效果不佳，且常伴有不良反应。 尽管 RA 的确切病因尚不清楚，但越来越多的证据表明 巨噬细胞 在疾病进展中发挥着关键作用。在 RA 受累关节中占主导地位的 M1 型巨噬细胞通过分泌促炎细 胞因子和活性氧 （ROS） 加剧滑膜炎和软骨损伤。鉴于巨噬细胞表型具有动态性且受局部微环境影响，目前的研究重点在于通过靶向促炎细胞因子或 ROS 来诱 导 M1 向 M2 极化。然而，抑制单个细胞因子并不足以消除炎症，因为炎症是由复杂的细胞因子网络驱动的。 近日，深圳大学医学部 董海峰 教授团队在 Cell 子刊 Cell Biomaterials 上发表了题为 ： Cerium-vanadium nanozyme/DNAzyme system for rheumatoid arthritis therapy through reactive oxygen species scavenging and inflammat ...